Elesclomol

Research use only, not for human use.

Elesclomol (STA-4783) is a small-molecule oxidative stress inducer.

Elesclomol (STA-4783) is a small-molecule oxidative stress inducer, exerts selective cytotoxicity by increasing intracellular concentrations of reactive oxygen species (ROS) and induces cell death via mitochondrial apoptosisin cancer cells; selectively kills cisplatin-resistant tumor cells through increased ROS, markedly enhances the therapeutic index of paclitaxel against human tumor xenograft models. Ovarian Cancer Phase 2 Clinical.

Apoptosis AnalysisCell Line:HSB2 cells Concentration:200 nM Incubation Time:18 hours Result:Increased the number of early and late apoptotic cells.

Animal Model:Cardiac Ctr1 knockout mice Dosage:10 mg/kg Administration:Subcutaneous injection; every three days from post-natal day 5 to 26 and once weekly until post-natal day 54 Result:Ameliorated severe cardiac pathology with a partial reduction in hypertrophy.

STA-4783 | STA4783 | STA 4783

Apoptosis

Apoptosis

HSP70

Cancer

Ovarian Cancer

488832-69-5

400.5177

C19H20N4O2S2

>98% (HPLC)

DMSO: ≥ 22 mg/mL

O=C(NN(C)C(C1=CC=CC=C1)=S)CC(NN(C)C(C2=CC=CC=C2)=S)=O

Propanedioic acid, 1,3-bis[2-methyl-2-(phenylthioxomethyl)hydrazide]

(-20℃)

With Ice Pack

≥ 2 years